Sun Yubo, Roberts Andrea, Mauerhan David R, Cox Michael, Hanley Edward N
Department of Orthopedic Surgery, Carolinas Medical Center, PO Box 32861, Charlotte, North Carolina, 28232.
J Orthop Res. 2018 Jan;36(1):309-317. doi: 10.1002/jor.23616. Epub 2017 Jun 13.
Phosphocitrate inhibits cartilage degeneration, however, the prospect of phosphocitrate as an oral disease modifying drug might be limited. The purpose of this study was to investigate the biological effects and disease-modifying activity of a phosphocitrate "analog," CM-01 (Carolinas Molecule-01), and test the hypothesis that CM-01 is a disease modifying drug for osteoarthritis therapy. The effects of CM-01 on calcium crystal-induced expression of matrix metalloproteinase-1 and interleukin-1 beta, cell-mediated calcification and production of proteoglycan by chondrocytes were examined in cell cultures. Disease-modifying activity was examined using Hartley guinea pig model of posttraumatic osteoarthritis. Cartilage degeneration in untreated and CM-01 treated guinea pigs was examined with Indian ink and Safranin-O-fast green. Levels of matrix metalloproteinase-13, ADAM metallopeptidase with thrombospondin type 1 motif 5, chemokine (C-C motif) ligand 5, and cyclooxygenase 2 were examined with immunostaining. CM-01 inhibited crystal-induced expression of matrix metalloproteinase-1 and interleukin-1β, reduced cell-mediated calcification, and stimulated the production of proteoglycan by chondrocytes. In Hartley guinea pigs, CM-01 not only reduced damages in articular surface but also reduced resorption of calcified zone cartilage. The reduction in cartilage degeneration was accompanied by decreased levels of matrix metalloproteinase-13, ADAM metallopeptidase with thrombospondin type 1 motif 5, chemokine (C-C motif) ligand 5 and cyclooxygenase 2. These findings confirmed that CM-01 is a promising candidate to be tested as an oral drug for human OA therapy. CM-01 exerted its disease-modifying activity on osteoarthritis, in part, by inhibiting the production of matrix-degrading enzymes and a molecular program resembling the endochondral pathway of ossification. © 2017 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 36:309-317, 2018.
磷酸柠檬酸可抑制软骨退变,然而,磷酸柠檬酸作为一种口服疾病改善药物的前景可能有限。本研究的目的是探究磷酸柠檬酸“类似物”CM - 01(卡罗莱纳分子 - 01)的生物学效应和疾病改善活性,并验证CM - 01是一种用于骨关节炎治疗的疾病改善药物这一假设。在细胞培养中检测了CM - 01对钙晶体诱导的基质金属蛋白酶 - 1和白细胞介素 - 1β表达、细胞介导的钙化以及软骨细胞蛋白聚糖产生的影响。使用创伤后骨关节炎的哈特利豚鼠模型检测疾病改善活性。用印度墨水和番红O - 固绿对未治疗和CM - 01治疗的豚鼠的软骨退变情况进行检测。用免疫染色法检测基质金属蛋白酶 - 13、含血小板反应蛋白基序的解聚素样金属蛋白酶5、趋化因子(C - C基序)配体5和环氧化酶2的水平。CM - 01抑制晶体诱导的基质金属蛋白酶 - 1和白细胞介素 - 1β的表达,减少细胞介导的钙化,并刺激软骨细胞产生蛋白聚糖。在哈特利豚鼠中,CM - 01不仅减少了关节表面的损伤,还减少了钙化区软骨的吸收。软骨退变的减轻伴随着基质金属蛋白酶 - 13、含血小板反应蛋白基序的解聚素样金属蛋白酶5、趋化因子(C - C基序)配体5和环氧化酶2水平的降低。这些发现证实CM - 01是一种有前景的候选药物,可作为治疗人类骨关节炎的口服药物进行试验。CM - 01对骨关节炎发挥其疾病改善活性,部分是通过抑制基质降解酶的产生以及类似于软骨内成骨途径的分子程序实现的。©2017骨科学研究协会。由威利期刊公司出版。《矫形外科学研究》36:309 - 317,2018年。